Medico firm Vivolution gains fresh capital to venture into the US market  

Fledgling Danish medico company Vivolution has gained DKK 55 m in fresh capital from two new investors, one of which is France's Seventure, and existing investors
Fledgling Danish medico company Vivolution has gained DKK 55 m (USD 9.4 m) in fresh capital from French venture firm Seventure and Denmark's Vecata, together with existing investors Vækstfonden, Dansk Innovationsinvestering and Dansk Kapitalanlæg. The money will be used to introduce Vivolution's wound healing technology on the US market. Vivolution is currently in contact with three leading international skin patch manufacturers which are interested in the Danish firm's technology.
Vivolution has two product groups that utilize the same patented technology: Vivostat autologous fibrin sealant is used during surgery to prevent and stop bleeding and oozing of body fluids, and Vivostat PRF autologous platelet rich fibrin is used to promote cell growth for a range of procedures including orthopaedic surgery and wound healing.
Tom Bjerg Lauritzen, co-founder and MD of Vivolution says the company's product for wound healing can especially benefit diabetes patients and the elderly. "It is a giant market. In Great Britain alone it is worth DKK 6 bn [USD 1 bn] annually. We are in competition with a lot of other companies on this market, but none of them can do the same as we can".
Hans Henrik Eriksen, MD of Vecata comments: "It is a very interesting company with an intriguing technology. It has great commercial potential, so we believe that we have made a really good investment. Vivolution will now have breathing space to develop and progress its business more aggressively." The news was reported by financial daily newspaper Børsen.
Link >  Vivolution   

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×